ResearcherHuntsman Cancer InstituteNo recent work listed

Mona Foth

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6507-8114; OpenAlex author ID A5088636025. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 13

Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper

Papers 2

Therapeutic Targeting of Autophagy in Pancreatic Cancer. Co-author DOI 10.1016/j.soc.2021.06.001 ↗
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2016.04.014 ↗

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Conan Kinsey · 1 shared paper, 2021 · strength 0.22
- Paper Therapeutic Targeting of Autophagy in Pancreatic Cancer. DOI 10.1016/j.soc.2021.06.001 ↗
Ignacio Garrido‐Laguna · 1 shared paper, 2021 · strength 0.22
- Paper Therapeutic Targeting of Autophagy in Pancreatic Cancer. DOI 10.1016/j.soc.2021.06.001 ↗
Thomas R. Jeffry Evans · 1 shared paper, 2016 · strength 0.04
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014 ↗
Colin William Steele · 1 shared paper, 2016 · strength 0.04
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014 ↗
Peter J. Bailey · 1 shared paper, 2016 · strength 0.04
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014 ↗
Simon T. Barry · 1 shared paper, 2016 · strength 0.04
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014 ↗
Nigel Balfour Jamieson · 1 shared paper, 2016 · strength 0.04
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014 ↗
C. Ross Carter · 1 shared paper, 2016 · strength 0.04
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014 ↗
Juliana B. Candido · 1 shared paper, 2016 · strength 0.04
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014 ↗
Jennifer P. Morton · 1 shared paper, 2016 · strength 0.04
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014 ↗
David Kuang-Fu Chang · 1 shared paper, 2016 · strength 0.04
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014 ↗
Owen James Sansom · 1 shared paper, 2016 · strength 0.04
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014 ↗
Andrew Victor Biankin · 1 shared paper, 2016 · strength 0.04
- Paper CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ccell.2016.04.014 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.